Annual report
7459.TEDINET S100OE94
Period2021-04-01 → 2022-03-31
Filed2022-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.29T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥3.21T | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥3.25T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.18T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.15T | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥45.6bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥38.6bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥62.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥53.0bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥68.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥63.9bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥57.3bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥57.3bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥49.2bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥29.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥23.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥38.0bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥34.4bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥34.8bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥39.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥33.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥1.71T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.68T | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥1.64T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.62T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.62T | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.06T | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.04T | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥649.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥638.9bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥607.4bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥592.8bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥572.7bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥243.2bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥222.7bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥260.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥240.0bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥224.5bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥230.0bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥220.6bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥61.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥34.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥56.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥63.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥63.6bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥24.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥23.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥43.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥16.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥16.0bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥49.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥30.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥15.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥140.14 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥113.96 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.8 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.09 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.13 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥131.41 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥106.8 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥165.33 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥145.15 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥149.91 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,525.72 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,490.98 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,382.88 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,233.52 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,154.93 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 31.0% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.1% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 12,801 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 12,971 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 13,599 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 13,868 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 14,151 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥26.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥28.3bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥69.8bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥28.2bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥24.8bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Operating income | ¥15.9bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥15.7bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥18.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥19.0bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥60.0bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.2bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥14.8bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥24.3bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥12.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥20.7bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥57.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥15.9bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥26.1bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥373.6bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥386.7bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥368.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥344.1bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥352.9bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥52.6bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥59.3bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥321.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥327.4bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥312.0bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥288.0bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥292.6bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥56.7bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥59.5bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥60.99 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.75 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥267.14 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥71.48 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.78 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥56.93 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥92.49 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥251.47 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥67.09 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥112.58 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥44 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥41 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,528.64 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,559.37 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,485.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,294.78 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,300.88 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 85.9% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.7% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.9% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 244,524,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 173 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 169 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 169 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 185 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 193 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥7m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥90m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥3.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥3.7bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥78.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥399m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥267m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥188m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | employees | at 2022-03-31 | 535 pure |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥71.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥71.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | segment assets | at 2022-03-31 | ¥28.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.7bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | employees | at 2022-03-31 | 2168 pure |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.05T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.05T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥349m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2022-03-31 | ¥444.9bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥25.9bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥8.1bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥8.2bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | employees | at 2022-03-31 | 9916 pure |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.18T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.17T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2022-03-31 | ¥1.16T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥16.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥18.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥13.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥3.29T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥3.29T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.63T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥45.2bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥0 |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥94m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥78.1bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | ¥269m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥89m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥243m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥69.1bn |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥69.1bn |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥3m |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | segment assets | at 2021-03-31 | ¥26.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥5.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥5.6bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥1.03T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥1.03T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥348m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2021-03-31 | ¥431.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥25.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥10.7bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥8.3bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥2.11T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥2.11T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥3.4bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2021-03-31 | ¥1.14T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥16.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥3.21T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥3.21T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥1.60T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥38.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,106
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of property plant and equipment inv cf | CurrentYearDuration | -15958000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YearDuration | 1231000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYearDuration | 255000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YearDuration | -2826000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYearDuration | -2919000000 | JPY |
| Purchase of investment securities inv cf | Prior1YearDuration | -2133000000 | JPY |
| Purchase of investment securities inv cf | CurrentYearDuration | -6808000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | Prior1YearDuration | 14660000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | CurrentYearDuration | 881000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | Prior1YearDuration | -2122000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | CurrentYearDuration | － | JPY |
| Payments of loans receivable inv cf | Prior1YearDuration | -0 | JPY |
| Payments of loans receivable inv cf | CurrentYearDuration | -3000000 | JPY |
| Collection of loans receivable inv cf | Prior1YearDuration | 8000000 | JPY |
| Collection of loans receivable inv cf | CurrentYearDuration | 3000000 | JPY |
| Net decrease increase in loans receivable from subsidiaries and associates inv cf | Prior1YearDuration | － | JPY |
| Net decrease increase in loans receivable from subsidiaries and associates inv cf | CurrentYearDuration | 318000000 | JPY |
| Other net inv cf | Prior1YearDuration | 1078000000 | JPY |
| Other net inv cf | CurrentYearDuration | -110000000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -2939000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -24343000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -1374000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -1444000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -3558000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -350000000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YearDuration | － | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYearDuration | 0 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -2000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -1000000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1YearDuration | － | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYearDuration | -3479000000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -8818000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -8818000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YearDuration | -2250000000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYearDuration | -2377000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -16003000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -16471000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 0 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 0 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 15506000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 20403000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 224541000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 240047000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 240047000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 260450000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 14 | |
| Number of unconsolidated subsidiaries accounted for using equity method | CurrentYearInstant | 1 | |
| Number of associates accounted for using equity method | CurrentYearInstant | 11 | |
| Accumulated depreciation buildings and structures | Prior1YearInstant | -94864000000 | JPY |
| Accumulated depreciation buildings and structures | CurrentYearInstant | -98921000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |